References
- Eriksson S. Alpha1-antitrypsin deficiency: lessons learned from the bedside to the gene and back again. Historic perspectives. Chest. 1989;95(1):181–189.
- Cole RB, Nevin NC, Blundell G, Merrett JD, McDonald JR, Johnston WP. Relation of alpha-1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population. Thorax. 1976;31(2):149–157.
- International Conference on Harmonisation. ICH harmonised tripartite guideline: guideline for good clinical practice [webpage on the Internet]. E6(R1). June 10, 1996. Available from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Accessed April 4, 2014.
- Sandhaus RA, Stocks J, Rouhani FN, Brantly M, Strauss P. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous). COPD. 2014;11(1):17–25.
- Stocks JM, Branity M, Pollack D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new α1−proteinase inhibitor, Zemaira. COPD. 2006;3(1):17–23.
- Stocks JM, Brantly ML, Wang-Smith L, et al. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol. 2010;10:13.
- Louie SG, Sclar DA, Gill MA. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency. Ann Pharmacother. 2005;39(11):1861–1869.
- Lund PE, Wassbäck G, Thomas O, Carlsson T, Schött U. Comparison of two infusion rates of antithrombin concentrate in cardiopulmonary bypass surgery. Perfusion. 2010;25(5):305–312.
- Gelfand EW, Hanna K; IGIV-C Increased Maximum Infusion Rate Study Group. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol. 2006;26(3):284–290.
- Ellis ME, al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother. 1992;36(1):172–179.
- Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468–1472.
- Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345–1353.
- Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest. 2003;123(5):1425–1434.
- Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J. 1998;11(2):428–433.
- American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.
- Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis. 2008;3:16.
- Ehlers MR, Gottlieb PA, Herold K, et al. Alpha-1 antitrypsin therapy in new-onset type 1 diabetes: interim results from Part I of the RETAIN study [webpage on the Internet]. Presented at: European Association for the Study of Diabetes, Berlin, Germany, October 1–5, 2012. Available from: http://www.immunetolerance.org/professionals/publications/alpha-1-antitrypsin-therapy-new-onset-type-1-diabetes-interim-results-par. Accessed April 4, 2014.